Acute Lymphoblastic Leukaemias (ALL) Recruiting Phase 2 Trials for Alemtuzumab (DB00087)

Also known as: Acute Lymphoblastic Leukemias / Acute Leukemia, Lymphoblastic / Acute Lymphoblastic Leukaemia / Acute Lymphoblastic Leukemia / Leukemia, Lymphoblastic, Acute / Lymphoblastic Leukemia, Acute / Leukemia, Acute Lymphoblastic / Leukaemia, Lymphoblastic, Acute / Acute Lymphoblastic Leukemia (ALL) / Leukemia, Lymphoblastic,Acute / Acute Leukaemia, Lymphoblastic / Acute lymphoblastic leukemia with failed remission / Leukemia lymphoblastic acute / Lymphoid leukaemia, acute / Acute lymphoid leukaemia / Lymphoid leukemia, acute / Acute lymphoid leukemia / ALL / Leukaemia lymphoblastic acute / Acute lymphocytic leukemia / Acute lymphatic leukaemia / Leukaemias acute lymphocytic / Acute lymphatic leukemia / Acute lymphocytic leukaemia

IndicationStatusPhase
DBCOND0073466 (Acute Lymphoblastic Leukaemias (ALL))Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03821610A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)Treatment
NCT00368355T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell GraftsTreatment